Pocket Program - CROI

Poster Listings
Session 75 CROI 2013
+ 349
Lyle McKinnon* 1,2 , B Nyanga1 , P Izulla1 , J Kwatampora1 , M Kimani1 ,
N Mugo3 , J Smith4 , O Anzala1,5 , J Kimani1,6 , and R Kaul1,2 1 2 3 Univ of Nairobi, Kenya;; Univ of Toronto, Canada;; Kenyatta Natl Hosp,
Nairobi, Kenya;; 4Univ of North Carolina at Chapel Hill, US;; 5Kenyan AIDS
Vaccine Initiative, Nairobi;; and 6Univ of Manitoba, Winnipeg, Canada
350
Jessica Prodger* 1 , R Gray2 , G Kigozi3 , F Nalugoda3 , RM Galiwango3 ,
T Hirbod4 , M Wawer2 , D Serwadda3 , R Kaul1 , and Rakai Genital
Immunology Res Group
1 2 Univ of Toronto, Canada;; Johns Hopkins Univ Bloomberg Sch of
Publ Hlth, Baltimore, MD, US;; 3Rakai Hlth Sci Prgm, Uganda;; and
4Karolinska Inst, Stockholm, Sweden
c Wednesday, 2:30-4 pm; Hall B2
Session 76–Poster Abstracts
Neutralizing Antibodies and How to Stimulate Them
351
Response during Primary Infection
Christoph Carter* 1 , G Wagner1 , G Hightower1 , L Hepler1 , G Caballero2 ,
S Little1 , S Kosakovsky Pond1 , P Phung3 , D Richman1,2 , and D Smith1,2 1 2 Univ of California, San Diego, La Jolla, US;; VA Hlthcare System, San
Diego, CA, US;; and 3Monogram Biosci Inc, South San Francisco, CA, US
352
Present in a Cohort of Long-term Non-progressors
Nuria Gonzalez* 1 , K McKee2 , E Yuste3 , J Mascola2 , and J Alcami1 1 2 Inst de Salud Carlos III, Madrid, Spain;; NIH, Bethesda, MD, US;; and
3Hosp Clin, Barcelona, Spain
353 HIV-1 Cross-Clade Neutralization Evolution in Elite
Carolina Ferreira* 1,2 , A Merino-Mansilla1,2 , A Llano2,3 , I Perez4 ,
I Crespo5 , L Llinas5 , F Garcia2,4 , J Gatell2,4 , E Yuste1,2 ,
and V Sanchez-Merino1,2 1Inst dInvestigacions Biomed August Pi i Sunyer, Barcelona, Spain;;
2 3 HIVACAT, Barcelona, Spain;; IrsiCaixa AIDS Res Inst, Hosp Germans
Trias i Pujol, Badalona, Barcelona, Spain;; 4Hosp Clin, Barcelona, Spain;;
and 5Ctr Esther Koplowitz, IDIBAPS, Barcelona, Spain
354 Adaptation of HIV-1 Envelope Glycoproteins to Selective
Melanie Bouvin* 1 , M Morgand1 , A Moreau1 , P Jestin2 , L Meyer2 ,
F Barin1 , and M Braibant1 1 2 INSERM U966, Univ Francois Rabelais, Tours, France and CESP
INSERM U1018, Univ Paris Sud, Hosp de Bicetre, Le Kremlin-Bicetre,
France
355
Nina Lin* 1,2 , C Becerril1 , S Moyo3 , J Makhema3 , R Musonda3 , M Essex3,4 ,
S Lockman2,3,4,5 , D Kuritzkes2,5 , and M Sagar2,5 1 2 Massachusetts Gen Hosp, Boston, US;; Harvard Med Sch, Boston, MA,
US;; 3Botswana-Harvard AIDS Inst Partnership, Gaborone;; 4Harvard Sch
of Publ Hlth, Boston, MA, US;; and 5 MA, US
356
John Moore* 1 , R Sanders1,2 , R Derking2 , R Depetris1 , A Cupo1 , P Klasse1 ,
R King3 , J-P Julien4 , I Wilson4 , and A Ward4 1 2 Weill Cornell Med Coll, New York, NY, US;; Academic Med Ctr,
Amsterdam, The Netherlands;; 3Intl AIDS Vaccine Initiative, New York,
NY, US;; and 4 359
during Suppressive Therapy
Viktor Dahl*
The Scripps Res Inst, La Jolla, CA, US
1 , M Gisslen2 , J Peterson3 , W Shao4 , S Spudich5 ,
R Price3 , and S Palmer1 1 2 Karolinska Inst, Stockholm, Sweden;; Sahlgrenska Academy at Univ of
Gothenburg, Sweden;; 3Univ of California, San Francisco, US;; 4Advanced Biomed Computing Ctr, SAIC-Frederick Inc, Frederick Natl Lab for
Cancer Res, MD, US;; and 5Yale Univ, New Haven, CT, US
360 Wild-type Viremia >50 Copies/mL Arising on cART: Identical
Viral Sequences Imply Expansion of a Clonal Source
Elizabeth Anderson* 1 , J Spindler1 , V Boltz1 , W Shao2 , T Uldrick3 ,
C Rhem4 , M Kearney1 , J Mellors5 , J Coffin6 , and F Maldarelli1 1HIV Drug Resistance Prgm, NCI-Frederick Natl Lab, MD, US;;
2Advanced Biomed Computing Ctr, SAIC-Frederick, Inc, NCI-Frederick
Natl Lab, MD, US;; 3HIV & AIDS Malignancy Branch, NCI, Bethesda,
MD, US;; 4Lab of Immunoregulation, NIAID, Bethesda, MD, US;; 5Univ of
Pittsburgh, PA, US;; and 6 361
Tufts Univ, Boston, MA, US
Lack of Viral Compartmentalization in Naïve and Memory
+
Gabriela Khoury* 1 , A Solomon1 , L Josefsson2 , F Wightman1 ,
S Palmer2 , P Cameron1,3 , and S Lewin1,3 1 2 Monash Univ and Burnet Inst, Melbourne, Australia;; Swedish Inst for
Infectious Disease Control and Karolinska Inst, Solna;; and 3Alfred Hosp,
Melbourne, Australia
362 Deep Sequencing Analysis of RT-SHIV Viremia in a Nonhuman
Primate Model of HIV-1 Therapy: Emergence of
Robert Kauffman* 1,2 , A Villalobos2,3 , J Higgins1 , R Schinazi2,3 ,
and T North1,2,3 1 2 Univ of California, Davis, US;; Emory Univ, Atlanta, GA, US;;
and 3VAMC, Decatur, GA, US
c Tuesday, 2:30-4 pm; Hall B2
Session 78–Poster Abstracts
Viral DNA Dynamics
363
RNA in Patients on Long-term Suppressive ART
Guillaume Besson* 1 , E Anderson2 , M Kearney2 , J Coffin3 ,
T Tanzosh2 , C Rehm4 , F Maldarelli2 , and J Mellors1 1 2 3 Univ of Pittsburgh, PA, US;; NCI-Frederick, MD, US;; Tufts Univ,
Boston, MA, US;; and 4NIAID, NIH, Bethesda, MD, US
364 Initial Therapy with Raltegravir Increases Clearance of
Matthew Strain* 1 , S Rought1 , S Lada1 , T Luong2 , C Woelk1 ,
A Andrade3 , D Kuritzkes4 , D Richman1 , and ACTG 5248
1Univ of California, San Diego, La Jolla and VA San Diego Hlthcare
System, US;; 2Univ of Michigan, Ann Arbor, US;; 3Johns Hopkins Univ,
Baltimore, MD, US;; and 4 365
T Cells for Eradication Strategies
Kersten Koelsch* 1,2 , J Murray2,3 , K McBride1,2 , Y Xu1,2 , M Bailey1,2 ,
S Emery2 , D Cooper1,2 , J Zaunders1 , A Kelleher1,2 , and PINT Study Team
1 2 St Vincents Hosp, Ctr for Applied Med Res, Sydney, Australia;; The
Kirby Inst for Infection and Immunity in Society, Univ of New South
Wales, Sydney, Australia;; and 3Sch of Mathematics and Statistics, Univ of
New South Wales, Sydney, Australia
366
drug cART in Rhesus Macaques
T North1,2 , Andradi Villalobos* 1 , J Deere2 , J Higgins2 , P Chatterjee1,3 ,
S-J Tao1,3 , J Kohler1,3 , P Luciw1,3 , and R Schinazi1,3 1Emory Univ Sch of Med and Emory Univ Ctr for AIDS Res, Atlanta, GA,
US;; 2Univ of California, Davis, US;; and 3Atlanta VAMC, Decatur, GA, US
c Monday, 2:30-4 pm; Hall B2
Session 77–Poster Abstracts
HIV Compartmentalization and Evolution on Therapy
357 Prevalence and Patterns of Residual Viremia in HIV +
Patients on Long-term Suppressive ART
Sharon Riddler* 1 , E Aga 2 , R Bosch 2 , M Bedison 1 , B Bastow 3 , J Eron 4 ,
R Gandhi 5 , J Mellors 1 , and A5276s Protocol Team
1 Univ of Pittsburgh, PA, US;; 2 Harvard Sch of Publ Hlth, Boston, MA, US;;
3 Social & Scientific Systems Inc, Silver Spring, MD, US;; 4 Univ of North
Carolina at Chapel Hill, US;; and 5 Massachusetts Gen Hosp, Boston, US
358 In-depth Phylogenetic Analyses of HIV-1 Evolution during
Long-term Suppressive Therapy
Lina Josefsson* 1 , N Faria 2 , S Eriksson 1 , E Sinclair 3 , W Shao 4 ,
P Hunt 3 , M Somsouk 3 , S Deeks 3 , F Hecht 3 , and S Palmer 1
1 Karolinska Inst and Swedish Inst for Infectious Disease Control, Solna;;
2 Rega Inst, Katholieke Univ Leuven, Belgium;; 3 Univ of California, San
Francisco, US;; and 4 Advanced Biomed Computing Ctr, SAIC-Frederick
Inc, NCI-Frederick, MD, US
32 20th Conference on Retroviruses and Opportunistic Infections
c Tuesday, 2:30-4 pm; Hall B2
Session 79–Poster Abstracts
Infected Cell Dynamics on Therapy
+ + 367
T Cells in HIV Naïve Patients
Silvia Nozza* 1 , D De Battista1 , L Galli1 , A Galli1 , M Ripa1,2 , L Della
Torre1 , S Chiappetta1,2 , G Tambussi1 , M Malnati1 , and A Lazzarin1,2 1 2 San Raffaele Sci Inst, Milan, Italy and Univ Vita Salute, San Raffaele Sci
Inst, Milan, Italy
368
+
T-Lymphocyte Responses
Liang Shan* 1 , C Durand1 , R Siliciano1,2 , and J Siliciano1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard
Hughes Med Inst, Baltimore, MD, US